Aarhus, Denmark — December 12, 2012 — Today CLC bio announced the participation in the European FP7 project, STATegra, and receives 1.3 million US Dollars out of the total $7.8M project budget.
STATegra aims to develop a user-friendly integral analysis platform for different omics data that is capable of providing a more efficient use of genomics technologies. As a first, this project will generate and integrate data obtained in proteomic, metabolomic and epigenomic experiments.
The STATegra project aims to provide novel methods and solid statistical foundations to the analysis of a number of different cutting-edge experimental datasets. CLC bio will make these new methods available in the context of their user-friendly software packages and enhance them with suitable visualisation tools. The combination of statistical and visual analysis is key in order to provide a supportive discovery environment for biomedical researchers. Within the overall project, also methods for the validation and design of follow-up studies are implemented. Utilizing and validating existing datasets, STATegra is also going to feed its experimental results back into the public domain.
STATegra project partners
The project partners in STATegra are CLC bio (Denmark), Biomax Informatics AG (Germany), Karolinska Institutet (Sweden), Imperial College of Science, Technology and Medicine (UK), Foundation for Research and Technology – Hellas (Greece), Institut d’Investigació Biomèdica de Bellvitge (Spain), University of Amsterdam (Holland), University of Leiden (Holland), the Ludwig-Maximilians University of Munich (Germany), University of California (USA). The project is coordinated by Dr. Ana Conesa from the Computational Medicine Institute of the Prince Felipe Research Centre (Spain).
About CLC bio
Contact CLC bio
Lasse Görlitz, VP of Communications
Tel: +1 (617) 765 0687